Plain-English translation of NCT05324332 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a new imaging agent called can detect prostate cancer as well as—or better than—an existing imaging agent called . Both agents work by attaching to special proteins found on prostate cancer cells, making tumors visible on a special type of scan called a PET/CT scan. The study will compare how well each agent finds cancer in the same patients.
Current imaging methods like CT and MRI sometimes miss small areas of prostate cancer. This medication targets a protein that prostate cancer cells produce in high amounts, which helps find cancers that other scans might miss. Researchers want to see if this new treatment option performs better than the current standard agent.
You likely qualify if…
You likely don't qualify if…
You will receive two PET/CT imaging scans on two consecutive days. For each scan, you will receive an injection of one of the imaging agents, then lie still in a scanner that takes pictures of your whole body. Each scan typically takes 30–60 minutes. The study takes place over just a few days, and afterward researchers will compare the two sets of images to see which agent provided clearer pictures of your cancer.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Peking Union Medical College Hospital
Enrollment target
~50 participants
Started
April 2022
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Sex
Male only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.